nVerses Capital’s Trueblue TBI Stock Holding History

nVerses Capital’s Portfolio TBI Stock Details TBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,400	Closed	-$35K	–	1376
2024 Q2	$35K	Buy	+3,400	New	+$36.8K	0.02%	660

Other funds holding TBI

Pzena Investment Management New York $34.1B AUM 23.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACM

Azarias Capital Management Berwyn, Pennsylvania $230M AUM 39.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

nVerses Capital's TBI Position: Q3 2024 in Review

nVerses Capital sold out of Trueblue (TBI) in Q3 2024, closing a stake of 3,400 shares — an estimated $35K sold.

nVerses Capital first reported a position in TBI in Q2 2024 and held it in 1 quarter. The position peaked at $35K in Q2 2024. 112 funds tracked by Wall St. Rank hold TBI as of Q3 2024.

nVerses Capital reported no remaining Trueblue position as of Q3 2024 after selling out during the quarter.
nVerses Capital sold 3,400 Trueblue shares in Q3 2024, an estimated $35K.
nVerses Capital first reported a position in Trueblue in Q2 2024 and held it in 1 quarter.
nVerses Capital's Trueblue position peaked at $35K in Q2 2024.
112 funds tracked by Wall St. Rank held Trueblue as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.